Vol 22, No 5 (2017)

Articles

MIKhAIL IVANOVICh DAVYDOV (K 70-LETIYu SO DNYa ROZhDENIYa)

- -.
Russian Journal of Oncology. 2017;22(5):236-237
pages 236-237 views

TRANSDERMAL FENTANYL: PHARMACOLOGICAL ASPECTS OF THERAPY IN CANCER PATIENTS. PART 2. APPLICATION FEATURES OF TRANSDERMAL FENTANYL FORMULATIONS

Sidorov A.V.

Abstract

Second part of the article summarizes factors influencing transdermal phentanyl pharmacokinetics. Data obtained from genetic studies of factors that could explain the individual variability in fentanyl activity are given. Main aspects of transdermal fentanyl administration with regard to the dosage, patch application and efficacy assessment as well as adverse effects and drug interactions are reviewed. Besides the most common medication errors related to transdermal opioid are analyzed.
Russian Journal of Oncology. 2017;22(5):238-245
pages 238-245 views

THYROID CANCER ASSOCIATED WITH MILTINODULAR GOITER

Kulikova M.N., Popova T.N., Tolstokorov A.S., Osincev E.U., Kurochkina E.N.

Abstract

The incidence rate of thyroid cancer is increasing, especially among young and middle-aged people. In most cases a malignant tumor can be diagnosed at the background of multinodular goiter. Differential diagnosis of malignant and benign tumors of the thyroid presents considerable difficulties. In this situation the decision on the extent of the surgical intervention seems to be important. In the article there are described features of the diagnosis and the choice of the surgical intervention for thyroid cancer associated with multinodular goiter. The morphological examination is the decisive method of diagnosis. The decision on the extent of the operative measure should be both individualized for each particular patient and proceed from the principles of oncological radicalism and functional effect.
Russian Journal of Oncology. 2017;22(5):246-249
pages 246-249 views

CLINICAL EXPERIENCE OF THE USE OF PD-1 INHIBITOR IN PATIENTS WITH NON-CELL LUNG CANCER WITH METASTATIC DAMAGE OF KIDNEYS AND ADRENALS

Sarantseva K.A., Yudin D.I., Okruzhnova M.A., Laktionov K.P.

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide. Despite the success over recent years in the treatment of NSCLC it has not yet been able to achieve good long-term survival. A new promising direction of NSCLC treatment in the second line is the use of immunotherapy by inhibitors of immune control points. This group of drugs radically changed the outlook on the prognosis of patients with disseminated NSCLC progressing on previous platinum-containing chemotherapy. The article presents the results of a clinical trial program for nivolumab and the analysis of clinical cases of its application in NSCLC patients with metastatic damage of the kidneys and adrenal glands.
Russian Journal of Oncology. 2017;22(5):250-254
pages 250-254 views

EXPERIENCE OF APPLICATION OF IPILIMUMAB IN COMBINED THERAPY OF SMALL-CELL LUNG CANCER. ANALYSIS OF DATA OF THE MULTICENTER RANDOMIZED RESEARCH CA 184-156, PHASE III

Kuzminov A.E., Bagrova S.G., Gorbunova V.A.

Abstract

Patients with advanced small cell lung cancer (SCLC) have an extremely poor prognosis against a background of standard therapy with a combination of etoposide with platinum drugs. In a randomized, double-blind of the CA184-156 phase 3, the efficacy and safety of ipilimumab or placebo in combination with etoposide and platinum preparations was evaluated as the first line treatment for disseminated SCLC. Material and methods. Randomization of patients was carried out in a ratio of 1:1 in the group of therapy: etoposide + platinum drug (carboplatin or cisplatin) + ipilimumab and etoposide + platinum preparation + placebo. Ipilimumab/placebo was administered at a dose of 10 mg/kg every 3 weeks, starting from the 3rd course of chemotherapy to the 6th course of chemotherapy. Further, in the absence of progression, maintenance therapy with ipilimumab/placebo was performed every 12 weeks. The main end point of the study was the assessment of overall survival (OS). Results. Out of 1,132 randomized patients, 954 received at least 1 administration of ipilimumab/placebo in combination with chemotherapy: ipilimumab, n = 478; placebo, n = 476. Median OS was 11.0 months in the chemotherapy group with ipilimumab and 10.9 months, in the chemotherapy group with placebo (RR, 0.94, 95% CI, 0.81-1.09, p =0,3775). The median progression-free survival was 4.6 months in the chemotherapy group with ipilimumab and 4.4 months in the chemotherapy group with placebo. (RR, 0.85, 95% CI, 0.75-0.97). The frequency and severity of side effects in the compared groups was similar, with the exception of diarrhea, rash, and colitis, which occurred significantly more frequent in the chemotherapy group with ipilimumab. The frequency of the discontinuation of therapy due to toxicity was higher in the chemotherapy group with ipilimumab (18% vs. 2%). Treatment-related deaths accounted for 5 in the chemotherapy group with ipilimumab and 2 - in the chemotherapy group with placebo. Conclusion. The addition of ipilimumab to chemotherapy did not contribute to an increase in OS in comparison with only chemotherapy in advanced SCLC patients. Unexpected adverse events in the chemotherapy group with ipilimumab were not noted. The study of the efficacy of ipilimumab in patients with disseminated SCLC in combination with PD1 inhibitors is ongoing. The results obtained in the analysis of data in a subset of 33 patients who participated in this study on the basis of the Department chemotherapy of N.N. Blokhin Russian Cancer Research Center, correspond to data obtained in the entire multicenter study CA184-156.
Russian Journal of Oncology. 2017;22(5):255-260
pages 255-260 views

PROCATHEPSIN B AND ENDOGENOUS INHIBITORS OF CYSTEINE PROTEASES IN TUMORS OF REPRODUCTIVE SYSTEM

Gashenko E.A., Lebedeva V.A., Russkikh G.S., Tsykalenko E.A., Pupyshev A.B., Brak I.V., Korolenko T.A.

Abstract

Cysteine proteases are regulated by the rate of the conversion of their inactive proforms into active forms and by specific endogenous inhibitors (cystatins), playing the important role in their regulation, especially in tumor growth and metastasis process. The content of procatepsin B, endogenous inhibitors of cysteine proteases cystatin B and cystatin C in biological fluids (blood serum, ascites fluid) in women with malignant neoplasms of the genital organs was studied. The comparative study of the concentration of procotepsin B, cystatin B and C in blood serum in practically healthy women and women with tumors of the reproductive system was carried out with the use of the enzyme immunoassay nethod. A high content of procatepsin B was shown to be found in all the study groups. The concentration of cystatin B was within the limits of significance and concentration of cystatin C was not changed in same patients in the study groups as compared with the control. The level of cystatin C in the serum was found to be correlated with the progression of the disease. In ascitic fluid (in comparison with blood serum), a sharp increase in the concentration of procatepsin B was revealed, reflecting its elevated extracellular secretion by tumor cells.
Russian Journal of Oncology. 2017;22(5):261-265
pages 261-265 views

TARGETED THERAPY IN COMPREHENSIVE MANAGEMENT OF METASTATIC COLON CANCER

Feoktistova P.S., Karaseva V.V., Khaylenko V.A., Sinelnikova O.A., Zharkova O.V.

Abstract

In recent years there has been strong progress in the treatment of metastatic colorectal cancer (mCRC) patients. The gain of the median of the overall survival (mOS) rate was more than doubled due to the introduction in the clinical practice of new compounds, the work of a multidisciplinary team, the timely registration of the disease progress, prescription of combined chemotherapy in the second line. The article presents the immediate and long-term results of a comparative study carried out on the basis of Oncology Centers, 122 mCRC patients were included, most of these patients - 87(71,3%) had surgery firstly, after that all patients were treated with standard chemotherapy FOLFOX-4 in the first-line treatment and FOLFIRI in the second line treatment, two groups of patients in the first and second lines of treatment received a combination of chemotherapy and targeted agents (bevacizumab, cetuximab), depending on the biological properties of the tumor (RAS-gene mutation status). The following results: metastatic progression-free survival (mPFS) for FOLFOX-4 group accounted for 12.0(±1.2) months; FOLFOX-4 + Bevacizumab - 20.3(±1.2) months, FOLFOX-4 + cetuximab - 22.0(± 2.0) months; mPFS for second-line therapy for FOLFIRI + bevacizumab group amounted to 24.0(± 3.1) months, FOLFIRI + cetuximab 22.5(±2.5) months, FOLFIRI-1 8.0(±2.4) months, FOLFIRI-2 6.4(±2.6) months; mOS for FOLFOX-4 group was 49.5(±2.5) months; FOLFOX-4 + Bevacizumab - 45.8(±2.1) months; FOLFOX-4 + cetuximab - 37.4(± 2.0) months; mOS for second-line therapy for FOLFIRI + bevacizumab group was 37.8(± 2.1) months, FOLFIRI + cetuximab - 31.5(± 2.3) months, FOLFIRI-1 - 26.3(± 1.8) months, FOLFIRI-2 - 26.2(± 1.9) months. The adverse events during the treatment of patients are reported.
Russian Journal of Oncology. 2017;22(5):266-273
pages 266-273 views

THE EFFECTIVENESS OF COMBINED TREATMENT OF DISSEMINATED MALIGNANT PLEURAL MESOTHELIOMA, A DESCRIPTION OF THE CLINICAL CASE

Karpenko T.D., Bychkov M.B.

Abstract

Modern approach to the individualization of the management of patients based on the careful observation for the minimal manifestations of the disease, prescription of pemetrexed at the first line of therapy, combination with platinum preparations and antiangiogenic targeted preparation bevazisumab allows control the disease at the advanced stage of pleural mezoteliom and support the good active state of patients during the long time.
Russian Journal of Oncology. 2017;22(5):274-276
pages 274-276 views

THE CONTRASTING PROPERTIES OF A NEW OIL IODINATED PREPARATION LINOYODOL IN VITRO AND IN VIVO

Granov A.M., Yakunina M.N., Fadeev A.J., Treshalina H.M., Molchanov G.V., Dolgushin B.I., Makovetskaja K.N.

Abstract

The research is devoted to the study of the contrasting properties of new iodinated oil drug Linoyodol (100% solution) by in vitro (monitoring: well-known contracter Omnipak and saline) and in vivo under intraarterial injection of 0.1-1.0 ml to a. femoralis of rats with a intramuscular tumor (n = 18) with the aid of X-ray and СT. In vitro contrasting was shown to be less intensive, than in Omnipak, and in vivo is manifested in a lethal dose of 1.0 ml of highly viscid solution. The conclusion was drawn concerning low contrasting of Linoyodol in vitro with the limitation of its administration of the viscid solution to rats into artery of rather small size. The last demands the use of larger laboratory animals with an artery of sufficient size and decrease of the viscosity of the injection solution.
Russian Journal of Oncology. 2017;22(5):277-280
pages 277-280 views

LEVELS OF GROWTH FACTORS AND THEIR RECEPTORS IN INTACT AND TUMOR TISSUES OF FEMALE MICE IN DYNAMICS OF THE MALIGNANT MELANOMA GROWTH

Kit O.I., Frantsiyants E.M., Bandovkina V.A., Kaplieva I.V., Trepitaki L.K., Rozenko L.Y., Cheryarina N.D., Pogorelova Y.A., Shulga A.V.

Abstract

The formation and growth of the tumor are accompanied with the development of new vasculature providing the neoplasm with nutrients for its growth and metastasis. Main agents for these processes are VEGF family that can be activated by various ways, including insulin growth factor (IGF) effects, epidermal growth factors (EGF), transforming growth factors (TGF) and fibroblast growth factor (FGF). The study included female C57BL/6 mice (n = 40) with B16/F10 melanoma transplanted subcutaneously. Changes in levels of VEGF-A, VEGF-C, VEGF-D and their receptors R1, R2 in dependence on the activity of IGF-I, IGF-II, EGF and FGF21 were studied by ELISA in tumor, perifocal area and intact tissues in the dynamics of B16/F10 melanoma growth using standard test systems. VEGF-A and VEGF-C were first to be activated in intact tissue of female mice with transplanted tumors, even prior to the tumor formation, which created conditions for the growth and development of the malignant tumor stroma. Later development of B16 melanoma was accompanied by the enhanced expression of VEGF growth factors and receptors in tumor and surrounding tissues. Main factors triggering angiogenesis in all samples included IGF2 and IGF1 which levels in the dynamics of melanoma growth correlated with VEGF-A values in tumor, its perifocal zone and intact tissues, and with VEGF-C in non-malignant tissue. The study demonstrated the multifactor staged activation of neoangiogenesis not only in B16 melanoma tissue but in surrounding and intact tissues as well.
Russian Journal of Oncology. 2017;22(5):281-287
pages 281-287 views

SENSITIVITY OF HUMAN TUMORS WITH VARIOUS EXPRESSION OF RECAF RECEPTOR TO AFP-CONTAINING COMPLEX OF AIMPILA IN VIVO

Smirnova G.B., Tsurkan S.A., Borisova Y.A., Tcherkassova J.R., Romanenko V.I., Kalishian M.S., Treshalina H.M.

Abstract

Experimental studies were carried out with non-covalent complex AIMPILA targeting on AFP receptors (ReCAF). The human subcutaneous xenografts were used with different ReCAF containing transplanted to immunodeficient mice Balb/c nude: colon cancer SW620/ReCAF +, liver cancer HepG2/ReCAF + + and breast cancer T47D/ReCAF + + +. IMPILA was administrated per os under beginning on 4th day after tumor transplantation daily for 5 or 10 days in the total doses of 0.5-2.0 mg/kg or 1.0-4.0 mg/kg, accordingly. The inhibiting effect (T/C < 42%) of AIMPILA was shown to increase in dependence on ReCAF containing on tumor cells: T/C = 70% (SW620/ReCAF +); T/C = 51% (HepG2/ReCAF + +) and T/C = 22% (T47D/ReCAF+++). On the more sensitive model in a series of experiences 10-times course for the treatment with the total dose of 4.0 mg/kg was detected and revealed to T/C = 15-37% (p < 0.05). In the pathomorphological investigation of the T47D/ReCAF+++ tumor there was verified the death of the majority of tumor cells under the treatment of AIMPILA via the apoptosis pathway.
Russian Journal of Oncology. 2017;22(5):288-291
pages 288-291 views

MEDICAL-SOCIAL PORTRAIT OF THE FEMALE PATIENT SUFFERING FROM THE ONCOLOGICAL DISEASE

Goleva O.P., Prudnikova O.N., Vyushkov D.M., Leonov O.V., Tasova Z.B.

Abstract

In the article there are presented results of the analysis of the questionnaire survey of 236 respondents, the executed survey according to specially developed questionnaire has been directed to the study of medico-social features of patients of the gynecologic unit of the Clinical Oncologic Dispensary. The typical patient was established to be typical urban resident aged of 52.6 ± 0.6 years, who has a college education (the highest or specialized secondary), satisfactory living conditions, married and equal smooth relationships in a family. On the one hand, the most part of women (76.3%) were quite active physically during the day (are involved in the work on a personal plot, the private house or played sports), from the other side - 33,8% of respondents had excess weight (25 < IMT < 30). 82.2% of women indicated that they had financial difficulties. The presence of such a harmful habit as smoking was demonstrated by 16.9% of respondents, however, the majority of women (56.7%) do not drink alcohol at all. The obstetric and gynecologic history included menses in the period from 12 to 14 years (79.3%), the most part of the interviewed cases did not show disorders in menses of various character. Average age of the beginning of sex life accounted for 19.5 ± 0.12 years, the average number of pregnancies per 1 woman amounted to 3.4 ± 0.12. Among the leading somatic diseases there were indicated diseases of the circulatory system (27.5%), digestive tract (19,4%), the musculoskeletal system (14%), urinary tract (9.9%) and pathology of respiratory organs (7.5%). The hereditary burdened malignant process took place in 42.6% of respondents, at the same time in most of respondents (51.3%) the disease was registered for the first time.
Russian Journal of Oncology. 2017;22(5):292-296
pages 292-296 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies